Holen Sie sich die Stockscreener-App
6.78
8.83%
0.55
Schlusskurs vom Vortag:
$6.23
Offen:
$6.23
24-Stunden-Volumen:
44,325
Relative Volume:
1.45
Marktkapitalisierung:
$12.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+37.80%
1M Leistung:
+32.68%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.90
$6.84
1-Wochen-Bereich:
$4.83
$6.84
52-Wochen-Spanne:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
781-439-5551
Adresse
100 SUMMIT DR, BURLINGTON
Vergleichen Sie NEUP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
6.78 | 8.64M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
Neuphoria Provides First Quarter 2025 Business Updates | NEUP St - GuruFocus
Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewswire
Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026SEC Filing - marketscreener.com
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Therapeutics Delays 10-Q Filing - TipRanks
Neuphoria Therapeutics (NEUP) Outlines Robust 2025 Drug Developm - GuruFocus
Neuphoria Therapeutics IncMerck Pays $15M Milestone, Extends Cash Runway To Q3 2026 - marketscreener.com
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans - GlobeNewswire
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 - GlobeNewswire
Neuphoria Therapeutics Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Neuphoria Therapeutics Inc Rings the Opening Bell - Nasdaq
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics’ Listing on Nasdaq - Global Legal Chronicle
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Why Evaxion Biotech Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga
Neuphoria Therapeutics Inc. (NEUP) - Zacks Investment Research
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Es liegen keine Finanzdaten für Neuphoria Therapeutics Inc (NEUP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
17.27%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):